# 1. Financial Performance ## A. Key Figures * **Revenue CAGR:** **49%** FY21–FY25 · **>30%** last two years * H1 FY26 Revenue: ₹25.3 Cr (–8.5% YoY) * **EBITDA:** **Marginally positive** H1 FY26 * **PAT:** **–₹78 Cr** H1 FY26 * **Gross Margin:** **~57%** reported · **>60%** ex-sampling/workshops * **Homegrown Brand Mix:** Increased from **24% to 38%** of turnover * **IPO Proceeds:** **₹27 Cr** allocated primarily to working capital ## B. Revenue Growth * **Strong Structural Growth:** Revenue expanded at a 49% CAGR since FY21, significantly outpacing the aesthetic market’s 9–10% trend, driven by rising demand for homegrown brands. * **Near-Term Headwinds:** H1 FY26 saw a decline in sales due to seasonal factors and deliberate business controls, though leadership emphasized long-term stability over short-term volume. * **Own Brand Momentum:** Homegrown product revenue nearly doubled year-on-year, with continued expansion planned amid higher-margin advantages. ## C. Profitability Trends * **Margin Leadership:** Gross margins benefit from a shift toward high-margin **homegrown brands (~70%)** versus imports (~60%), with structural potential above 60% after adjusting for non-recurring P&L items. * **Profitability Pressures:** Despite margin gains, bottom-line performance weakened due to elevated employee costs and stagnant top-line growth in H1. * **Sustainable Model Focus:** Management prioritizes long-term PAT positivity, rejecting high-burn models, and emphasizing operational discipline over aggressive ad-driven scaling. ## D. Cash Flow Health * **Cash Flow Rebound Underway:** Despite a rise in the net cash conversion cycle to **450 days**, recent monthly trends show improvement, with expectations of recovery in H2 driven by tighter controls and working capital optimization. * **Strategic Funding Use:** Post-IPO, cash flow discipline has improved; proceeds are being deployed to reduce short-term debt reliance and strengthen liquidity foundations. ## E. Balance Sheet Use * **Working Capital Priority:** The majority of IPO proceeds are directed toward enhancing receivables management and funding scalable growth initiatives, reinforcing financial resilience. --- # 2. Product & Portfolio Mix ## A. Key Figures * **Customer Base Growth:** **~3,000** total customers · **>900** new customers (H1) * **Product Mix Shift:** Device contribution down to **14%** from 28% · Consumables gross margin **>50%** * **SKU Count:** **154** currently · Expected to reach **163–164** by year-end * **New Launch Timeline:** Exovia launch expected **end of this month/early next month** · Shipments later this year ## B. Brand Contribution * **Strategic Evolution:** Transitioned from distributor to innovation-driven, asset-light model with hybrid global-local strategy and **expanded national footprint**. * **Portfolio Leadership:** Positions as India’s broadest aesthetic portfolio player, targeting global scale across aesthetics, skincare, and healthcare. * **Brand & Channel Expansion:** Aakaar brand gaining traction with **doctor-accepted, science-backed launches** like Tubelight GFC; strategic shift toward OTC model to mirror mass-market success of brands like Crocin. * **Structural Reorganization:** Split into dedicated devices and consumer divisions to sharpen focus and drive growth in high-margin consumables. ## C. Injectable & Aesthetic Performance * **Niche Dominance:** Strong positioning in **chemical peels** with India-specific formulations for melasma and pigmentation, differentiating from global players. * **Treatment Advantage:** Aesthetic injectables deliver near-permanent results, fueling demand for procedures like jawline and chin enhancement. * **Device Portfolio:** Offers capital equipment (e.g., lasers, hydro facials) with one-time purchase dynamics, though declining share reflects strategic de-emphasis. ## D. Regenerative & SKU Expansion * **High-Value Regenerative Push:** Launch of **Exovia** with Italian partner VM marks entry into premium exosome therapy, targeting metro consumers and enabling end-to-end hair care solutions. * **SKU Scalability & Pricing Power:** Portfolio expansion includes **50-unit vial option**, enhancing price competitiveness against Botox and broadening market access. * **Recurring Revenue Model:** Home-care and OTC products drive stickiness and long-term revenue, with potential to scale in growing consumer skincare channels. --- # 3. Customer & Channel Reach ## A. Key Figures * **Doctor Base:** **~14,000** medical professionals covered · **~6,000** plastic surgeons engaged * **Field Force:** **100+** personnel covering **~8,000** doctors bi-monthly · **25–27%** annual MR attrition (in line with industry) ## B. Doctor Base Growth * **Core Prescriber Focus:** Revenue exclusively doctor-mediated, targeting dermatologists, plastic surgeons, and aesthetic specialists across India with deep IADVL-linked outreach. * **Usage Expansion:** Growth driven by rising per-customer utilization and loyalty, reflected in increasing multi-product adoption among doctors. ## C. Field Force Coverage * **High-Touch Model:** Field teams enable real-time demand conversion; operations restructured into three product divisions to strengthen personalized engagement post-COVID. * **Stable Leadership, Scalable Footprint:** Despite moderate MR turnover, senior sales leadership shows long tenure and internal promotion, supporting consistent execution amid expansion from 30–40 to 140 employees over 5–6 years. * **Channel Innovation:** Exploring doctor-as-retail model inspired by Kama/Nykaa; cautious organic e-commerce rollout planned to preserve margins. ## D. New Customer Adds * **Strong Market Penetration:** Robust customer acquisition continues with **900+ new customers** added in first half, building on over 2,600 added last year. * **Revenue Decoupled from Volume:** Recent de-growth attributed to extended payment cycles, not customer attrition, with active points of sale sustained via repeat usage and home-care brand traction. * **D2C Reinforces Doctor Ecosystem:** Direct-to-consumer strategy designed to funnel patients back to physicians, enhancing trust and reducing retention costs. --- # 4. Manufacturing & Supply Chain ## A. Local Production * **Headline:** Local manufacturing of polynucleotide-based treatments, including salmon DNA (salmon facial), established in India using imported raw materials. ## B. Import Dependencies * **Headline:** Strategic import of advanced medical aesthetic devices from Korea, Spain, Italy, and Austria supports product portfolio while maintaining capital efficiency. * **Headline:** Own-brand formulations produced via structured manufacturing partners, balancing scale and profitability. ## C. Inventory Management * **Headline:** Elevated inventory levels driven by regulatory re-licensing post-transition from private limited structure. * **Headline:** Higher stockpiles also reflect import buildup for international brands and new division launches, with target to normalize to **90–120 days** of inventory. ## D. Logistics Infrastructure * **Headline:** Fully integrated logistics supply chain built in-house, enhancing control and scalability. * **Headline:** Backend infrastructure investments in billing, reporting, and **MIS software** driving operational efficiency post-funding. --- # 5. Innovation & Regulatory Progress ## A. Regulatory & Approval Milestones * **Headline:** Achieved **US FDA approval** for both toxin and filler product lines, marking a pivotal step in challenging dominant players in the aesthetic market. * **Headline:** Strategic partnerships with **Hugel (Korea)** and **Croma-Pharma (Austria)** enable access to high-quality, approved products, enhancing credibility and market reach. * **Headline:** Regenerative product launches expected in India by **December or January**, with advanced polynucleotide-based medical devices in the regulatory pipeline. ## B. Clinical & Product Pipeline * **Headline:** In-house innovation gaining traction with **DRS 1512** in clinical studies and positive pilot results, supporting future licensing and international expansion. * **Headline:** Pipeline strategically focused on **medical injectable aesthetics**, backed by **three-year visibility planning** and KOL-driven development. * **Headline:** Expansion into serious dermatology via a psoriasis product developed with **Invex (Piramal Healthcare)**, supported by clinical data from **600+ patients**. ## C. Product Differentiation & Innovation * **Headline:** **Regenera** platform establishes early leadership in **regenerative aesthetics**, featuring **four exosome-based divisions** including proprietary technology. * **Headline:** Portfolio includes **plant-derived, synthetic, and proprietary exosome-generating systems**, creating differentiated offerings in a high-growth segment. * **Headline:** Developing **proprietary formulation processes** and a **dual-label hair transplant device**, though reliant on distribution rights rather than patents. ## D. KOL & Market Engagement * **Headline:** Extensive medical education footprint with **280+ doctors trained on injectables** and **329 trained on psoriasis**, driving adoption and loyalty. * **Headline:** Strong **KOL network and conference presence** (e.g., IMCAS, AMWC) inform product development aligned with global and local trends. * **Headline:** Listing status elevates profile, positioning company as a **preferred channel partner** for multinationals seeking Indian market entry. --- # 6. Risks & Payment Norms ## A. Key Figures * **Receivable Days Target:** **<100 days** (current: **130 days**) · **Longer-term goal: <60 days** ## B. Receivable Days * **Cash Flow Focus:** Aggressive push to reduce industry-high receivable days through **stringent credit controls**, including restricting sales to late-paying customers and tighter terms for new clients. * **Strategic Trade-off:** **Moderated sales volume** accepted as a consequence of improved collections, prioritizing cash flow sustainability over unrestrained growth. * **Catalysts for Improvement:** Recent **FDA approvals for two brands** and differentiated product pipeline enhancing customer trust, supporting better payment discipline. * **Industry Challenge:** B2B model with doctors entrenched in delayed payment norms; company aims to be **first aesthetic firm on NSE Emerge to achieve positive cash flow**. ## C. Industry Competition * **Portfolio Edge:** Claims **broadest product coverage in India**, enabling category-level differentiation and competitive resilience. * **Pricing Leverage:** Maintains **more competitive pricing than global peers** (e.g., Allergan, Galderma), strengthening value proposition in domestic market. * **Aspirational Shift:** Management anticipates potential **industry-wide improvement in payment norms**, inspired by early peer trends and tightening compliance. ## D. Margin Pressures * **E-commerce Caution:** Delaying online expansion despite rebranding for digital, citing risks of **margin erosion and negative profitability**. ## E. Regulatory Transitions * **Compliance Advantage:** Operates in **highly unorganized market** with widespread unlicensed imports, but maintains full regulatory compliance via product registrations. * **Customer Dynamics:** Core buyers (doctors, dermatologists) follow **industry-standard delayed payments**, which the company is actively challenging through policy enforcement. --- # 7. Guidance & Outlook ## A. Key Figures * **FY26 Revenue Growth Guidance:** **25%-30%** momentum expected * **Per-Person Productivity:** **INR5 lakh** recorded last year (temporary dip noted) ## B. FY26 Revenue Target * **Seasonal Upside:** H2 revenue momentum expected to strengthen on festive demand, inventory drawdown, and tighter credit controls. * **Strategic Growth Ambition:** Management reaffirmed commitment to **25%-30% CAGR** trajectory, aligned with ambition to lead India’s aesthetic market. * **Market Opportunity:** Aakaar Medical targeting **INR1,000 Cr revenue** in a **$3–5 Bn** total addressable market, signaling long-term scale potential. ## C. Margin Improvement * **Margin Expansion Path:** EBITDA margin improvement anticipated over 1–2 years as new hires ramp up and operational leverage normalizes. * **Productivity Focus:** Division-specific structures in place to enhance accountability and drive **per-person productivity recovery**. ## D. Long-Term CAGR * **Growth Rebound Expected:** Current de-growth reflects deliberate tightening of credit and receivables; **growth recovery anticipated in H2**. * **Franchise Potential:** Comprehensive hair care offering emerging as a **future growth pillar** with scalable franchise potential.